MX2010002692A - Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos. - Google Patents

Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos.

Info

Publication number
MX2010002692A
MX2010002692A MX2010002692A MX2010002692A MX2010002692A MX 2010002692 A MX2010002692 A MX 2010002692A MX 2010002692 A MX2010002692 A MX 2010002692A MX 2010002692 A MX2010002692 A MX 2010002692A MX 2010002692 A MX2010002692 A MX 2010002692A
Authority
MX
Mexico
Prior art keywords
dioxoles
benzo
synthesis
catechols
deuterated
Prior art date
Application number
MX2010002692A
Other languages
English (en)
Inventor
Andrew D Jones
Robert E Zelle
I Robert Silverman
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of MX2010002692A publication Critical patent/MX2010002692A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un proceso conveniente y eficaz para la síntesis de d2-benzo[d][1,3]dioxoles.
MX2010002692A 2007-09-13 2008-09-12 Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos. MX2010002692A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99356507P 2007-09-13 2007-09-13
PCT/US2008/010643 WO2009035652A1 (en) 2007-09-13 2008-09-12 Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof

Publications (1)

Publication Number Publication Date
MX2010002692A true MX2010002692A (es) 2010-06-01

Family

ID=40116877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002692A MX2010002692A (es) 2007-09-13 2008-09-12 Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos.

Country Status (8)

Country Link
US (2) US8822498B2 (es)
EP (2) EP2727915B1 (es)
JP (1) JP5647519B2 (es)
CN (1) CN101855218A (es)
AU (1) AU2008299921B2 (es)
CA (1) CA2698808A1 (es)
MX (1) MX2010002692A (es)
WO (1) WO2009035652A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2396365T3 (es) * 2005-07-29 2013-02-21 Concert Pharmaceuticals Inc. Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CA2698808A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
ME03652B (me) * 2011-05-18 2020-07-20 Vertex Pharmaceuticals Europe Ltd Deuterisani derivati ivakaftora
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
US20120302526A1 (en) * 2011-05-27 2012-11-29 Regents Of The University Of Colorado, A Body Corporate Methods for treating post-traumatic stress disorder
CN102924426B (zh) * 2012-11-14 2014-07-02 广西师范大学 胡椒乙胺缩5-氯水杨醛及其合成方法和应用
CN102942554B (zh) * 2012-11-14 2014-05-28 广西师范大学 胡椒乙胺缩水杨醛及其合成方法和应用
PL3143011T3 (pl) * 2014-05-13 2021-07-19 F. Hoffmann-La Roche Ag Deuterowane związki heterocykliczne i ich zastosowanie jako środki obrazujące
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN103980271B (zh) * 2014-05-30 2015-12-02 天津长森药业有限公司 黄藤素及其类似物的制备方法
JP6917144B2 (ja) * 2014-07-29 2021-08-11 シンセン ハイタイド バイオファーマシューティカル リミテッド ベルベリン塩、ウルソデオキシコール酸塩ならびに組み合わせ、その調製および適用方法
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
MA42954A (fr) 2015-09-25 2018-08-01 Vertex Pharmaceuticals Europe Ltd Potentialisateurs cftr deutérés
EP3398942B1 (en) 2016-02-25 2021-01-27 Shenzhen TargetRx, Inc. Substituted oxadiazole chemical compound and composition containing said chemical compound and use thereof
KR101970326B1 (ko) * 2016-08-05 2019-04-18 고려대학교 산학협력단 당 부가된 엔클로미펜, 이의 제조방법 및 이를 포함하는 약학적 조성물
US11708331B2 (en) 2017-12-01 2023-07-25 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
CN113735847B (zh) * 2021-09-10 2022-06-07 四川大学 一种盐酸小檗碱的合成制备方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
WO1989001342A2 (en) * 1987-08-07 1989-02-23 Mallinckrodt, Inc. Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
WO1998047514A1 (en) 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
IT1291320B1 (it) 1997-05-08 1999-01-07 Borregaard Italia Spa Procedimento per la preparazione di composti aromatici contenenti un sistema eterociclico
AU3108097A (en) * 1997-06-10 1998-12-30 Synthon B.V. 4-phenylpiperidine compounds
JP2001518520A (ja) 1997-10-03 2001-10-16 キャリー メディカル コーポレイション ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU753422B2 (en) 1998-03-17 2002-10-17 Pfizer Products Inc. Bicyclo(2.2.1)heptanes and related compounds
US20030187269A1 (en) * 1998-04-17 2003-10-02 Curzons Alan David Novel process
GB9817195D0 (en) * 1998-08-07 1998-10-07 Smithkline Beecham Plc Novel process
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
EP1146871A4 (en) 1999-01-28 2002-04-17 Bristol Myers Squibb Co HETEROCYCLIC ANTIDEPRESSANT COMPOUNDS
US20030055070A1 (en) 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
GB9916187D0 (en) 1999-07-09 1999-09-08 Smithkline Beecham Plc Novel process
IL137937A0 (en) 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
ATE234299T1 (de) * 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20040229911A1 (en) 2000-05-17 2004-11-18 Pfizer Inc New pharmaceutical combinations for NOS inhibitors
DOP2001000154A (es) 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
EP1181933A3 (en) 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
US6369051B1 (en) 2000-07-06 2002-04-09 American Home Products Corporation Combinations of SSRI and estrogenic agents
US20020077323A1 (en) 2000-07-12 2002-06-20 Mclean Stafford Use of delta opioid receptor ligands and serotonin reuptake inhibitors in the treatment of chemical dependencies
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US6696450B2 (en) 2001-04-04 2004-02-24 Wyeth Serotonergic agents with long-acting in vivo effects
US6656951B2 (en) 2001-04-24 2003-12-02 Wyeth 8-aza-bicyclo[3.2.1]octan-3-ol derivatives of 2,3-dihydro-1,4-benzodioxan as 5-HT1A antagonists
WO2002088145A1 (en) 2001-04-26 2002-11-07 Wyeth AZABICYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZACYCLOPENTA[a]NAPHTHALENE AS 5-HT1A ANTAGONISTS
US6821981B2 (en) 2001-04-26 2004-11-23 Wyeth Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists
US6861427B2 (en) 2001-04-26 2005-03-01 Wyeth Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-HT1A antagonists
US6815448B2 (en) 2001-05-07 2004-11-09 Wyeth Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
CA2459304A1 (en) 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
US20050009815A1 (en) 2001-11-27 2005-01-13 Devita Robert J. 4-Aminoquinoline compounds
JP2005519876A (ja) 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
US20050014848A1 (en) 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
US20040248956A1 (en) 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
JP4458853B2 (ja) 2002-03-13 2010-04-28 シェーリング コーポレイション Ｎｋ１アンタゴニスト
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
US20040224943A1 (en) 2003-02-19 2004-11-11 Leventer Steven M. Method of lowering body temperature with (R) - 2,3-benzodiazepines
JP4680897B2 (ja) 2003-06-27 2011-05-11 ファイザー・プロダクツ・インク Ｇｓｋ−３阻害薬としてのピラゾロ［３，４−ｂ］ピリジン−６−オン類
US20050070577A1 (en) 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
WO2005018541A2 (en) 2003-07-11 2005-03-03 Pharmacia Corporation Cox-2 inhibitor and serotonin modulator for treating cns damage
US7276608B2 (en) 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
JP2007503396A (ja) 2003-08-22 2007-02-22 ファルマシア コーポレイション 新形成の治療のためのシクロオキシゲナーゼ−２選択的阻害剤及びセロトニン−調節剤の組成物
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
RU2006126122A (ru) 2003-12-19 2008-01-27 Бристол-Маерс Сквибб Компани (Us) Азабициклические гетероциклы как модуляторы каннабиоидного рецептора
WO2005107716A1 (en) 2004-03-25 2005-11-17 Cadila Healthcare Limited Controlled release paroxetine-containing tablets based on a core and a coating
FR2869033B1 (fr) 2004-04-20 2006-06-02 Rhodia Chimie Sa Procede de preparation de methylenedioxybenzene
US20050266082A1 (en) 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
KR100920856B1 (ko) 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
US20080213381A1 (en) 2005-03-14 2008-09-04 Pharmaceutical Industries Limited Oral Drug Delivery System
KR20070009934A (ko) 2005-07-16 2007-01-19 주식회사 씨티씨바이오 염산 파록세틴 서방정 및 이의 제조방법
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
ES2396365T3 (es) * 2005-07-29 2013-02-21 Concert Pharmaceuticals Inc. Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina
AU2006275702A1 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
JP5153629B2 (ja) 2005-08-02 2013-02-27 ルピン・リミテッド 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
US20070112031A1 (en) 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
AU2006299424A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
WO2008016677A2 (en) 2006-08-02 2008-02-07 Auspex Pharmaceuticals, Inc. Preparation and utility of deuterated amphetamines
WO2008030382A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
CA2698808A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
WO2011011420A2 (en) * 2009-07-21 2011-01-27 Auspex Pharmaceuticals, Inc. 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor

Also Published As

Publication number Publication date
AU2008299921A1 (en) 2009-03-19
US20140336387A1 (en) 2014-11-13
AU2008299921B2 (en) 2012-03-01
AU2008299921A8 (en) 2010-04-08
EP2200997B1 (en) 2013-11-06
US20090143432A1 (en) 2009-06-04
CN101855218A (zh) 2010-10-06
JP2010539166A (ja) 2010-12-16
EP2727915A1 (en) 2014-05-07
US9315483B2 (en) 2016-04-19
JP5647519B2 (ja) 2014-12-24
EP2200997B9 (en) 2016-01-13
US8822498B2 (en) 2014-09-02
EP2200997A1 (en) 2010-06-30
CA2698808A1 (en) 2009-03-19
WO2009035652A1 (en) 2009-03-19
EP2727915B1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
MX2010002692A (es) Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos.
SG10201811715YA (en) Intermediates and methods for the synthesis of halichondrin b analogs
DE502006006854D1 (de) Substituierte benzo (d) isoaxol-3-yl-amin-verbindungen als analgetika
HK1089444A1 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
ZA200800785B (en) Novel benzo [D] [1,3]-dioxol derivatives
EA200801959A1 (ru) Высокоразветвленный полипропилен
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
SG158848A1 (en) Method for producing annelated piperazin-2-one derivatives and intermediates of said method
TW200619215A (en) Asymmetric synthesis of dihydrobenzofuran derivatives
MX2007011668A (es) Mezclas de caucho de silicona de reticulacion por adicion autoadhesivas, metodo para la produccion de las mismas, metodo para producir partes moldeadas compuestas y uso de las mismas.
TW200613256A (en) Photoactive compounds
TW200619205A (en) A method for preparing irbesartan and intermediates thereof
IL175253A0 (en) A process for preparing pyrrole derivatives
TW200728310A (en) Process for the preparation of ferri-succinylcasein
GB0621805D0 (en) Organic compounds
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
ATE415395T1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
UA87710C2 (ru) Способ получения производных [1,4,5]-оксадиазепина
WO2008019356A3 (en) Process for the preparation of substituted-1,2,3,4-tetrahydroisoquinoline derivates
IL181364A0 (en) Process for the synthesis c-2,c-3 substituted n-alkylated indoles useful as cpla2 inhibitors
AP2277A (en) Process for production of 1,2,2,2-tertafluoro ethyl difluoro methyl ether.
IL179141A (en) Biotransformation of colchicinoid compounds
TW200734321A (en) Benzo [b] thiophen derivatives and a process for producing benzo [b] thiophen derivatives
TW200716656A (en) Processes for the preparation of paclitaxel
MY136288A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
FA Abandonment or withdrawal